Biomedical Engineering Reference
In-Depth Information
78. Klemens SP, Cynamon MH, Swenson CE, Ginsberg RS. Liposome-
encapsulated-gentamicin therapy of Mycobacterium avium complex infec-
tion in beige mice. Antimicrob Agents
Chemother
, 1990;34:967-970.
79. Deol P, Khuller GK. Lung specii c stealth liposomes:stability, biodistribution
and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys
Acta, 1997:1334:161-172.
80. Ahmed M, Ramdan W, Rambhu D, Shakeel F.Potential of nanoemulsions for
intravenous delivery of rifampicin. Pharmazie, 2008;63:806-811.
81. Anisimova, Y.V.
et al
(2000). Nanoparticles as anti-tuberculosis drugs carriers:
ef ect on activity against
Mycobacterium tuberculosis
in human-monocyte
derived macrophages J. Nanopart. Res. 2, 165-171.
82. M. Silva, N.L. Ricelli, O. EL Seoud, C.S.Valentim, A.G. Ferreira, D.N.
Sato, C.Q.F Leite, E I Ferreira. Potential tuberculostatic agent:micelle-
forming pyrazinamide prodrug, Arch.Pharm. Chem. Life Sci. 339(2006)
283-290.
83. P.Sabitha, J.VIjaya Ratna and K. Ravindra Reddy. Design and evaluation of
controlled release chitosan-calcium alginate microcapsules of anti-tubercu-
lar drugs for oral use. International Journal of Chem Tech Research, 2010
Vol 2,No1, pp88-98.
84. Sung JC. Dry powdere nitoimidazopyran antibiotic PA-824 aerosol for inha-
lation. Antimicrob Agents
Chemother
. 2009;53(4):1338.
85. Ain Q Sharma S,Garg SK, Khuller GK:Role of poly [DL-lactide co-glycolide]
in development of a sustained oral delivery system for antitubercular drugs.
Int J Pharm
2002, 239(1-2):37-46.
86. R. Pandey, A. G.K.Khuller. Subcutaneous nanoparticle based antitubercu-
lar characterization chemotherapy in experimental model. J Antimicrob
Chemother (2004) 54, 266-268.
87. Pandey R.
et al
(2005) Oral solid lipid nanoparticle-based antitubercular che-
motherapy,
Tuberculosi s
85, 415-420.
88. O'Hara, P.and Hickey, A.J.(2000). Respirable PLGA microspheres containing
rifampicin for treatment of tuberculosis:manufacture and characterization.
Pharm. Res 17, 955-96
89. Hwang, SM
et al
(2008).Delivery of ol oxacin to the lung and alveolar mac-
rophages via hyaluron microspheres for the treatment of tuberculosis. J.
Control. Release, 129, 100-106.
90. Sarogi, G.K.
et al.
(2011). Mannosylated gelatine nanoparticles bearing
isoniazid for ef ective management of tuberculosis. J. Drug Target 19,
2127-2192.
91. .K. Ohasi, T. Kabasawa, T.Ozeki, H. Okada. One-step preparation of rifam-
picin/poly(lactic-co-glycolic acid) nanoparticles containing mannitol
microspheres using a four l uid nozzle spray drier for inhalation therapy of
tuberculosis,
J Control Release
135 (2009).
92. Jae Hyung Park, Guruswamy Sarvanakumar, Kwangmeung Kim, Ick Chan
Kwon. Targeted delivery of low molecular drugs using chitosan and its deriv-
atives. Advanced drug delivery reviews, 62 (2010), 28-41.
